The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Feasibility to obtain a chemogram in circulating tumorigenic cells to guide further treatments in refractory solid tumors.
Antonio Cubillo
No relevant relationships to disclose
Antonio Calles
No relevant relationships to disclose
Pedro P. López-Casas
No relevant relationships to disclose
Mark Ricigliano
Employment or Leadership Position - CellPath Therapeutics
Emiliano Calvo
No relevant relationships to disclose
Ignacio Duran
No relevant relationships to disclose
Fernando López-Ríos
No relevant relationships to disclose
Margarita Rodriguez
No relevant relationships to disclose
Manuel Hidalgo
Employment or Leadership Position - CellPath Therapeutics (U)